Sevelamer Carbonate
NDC Package 0179-0236-70

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Sevelamer Carbonate is sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Marketed by Kaiser Foundation Hospitals, this product is identified by NDC 0179-0236 and is authorized under FDA application NDA022127.

Identification & Billing

NDC Package Code
0179-0236-70
Package Description
30 TABLET, FILM COATED in 1 BOX, UNIT-DOSE
Product Code
11-Digit Billing Format
00179023670

Clinical Specifications

Proprietary Name
Sevelamer Carbonate
Dosage Form
-
Usage Information
Sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Sevelamer works by holding onto phosphate from the diet so that it can pass out of your body.

Regulatory & Marketing

Labeler Name
Kaiser Foundation Hospitals
FDA Application #
NDA022127
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
12-18-2017
End Marketing Date
09-30-2018
Listing Expiration
09-30-2018
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0179-0236-70 identifies a specific commercial package of 30 tablet, film coated in 1 box, unit-dose of Sevelamer Carbonate, labeled by Kaiser Foundation Hospitals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Kaiser Foundation Hospitals on December 18, 2017. The current certification is valid through September 30, 2018.

What are the primary indications for this medication?

Sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Sevelamer works by holding onto phosphate from the diet so that it can pass out of your body.

How is this Kaiser Foundation Hospitals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00179023670. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0179-0236-70
11-Digit CMS (5-4-2)
00179-0236-70

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.